306 related articles for article (PubMed ID: 33275800)
1. GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis.
Koller PB; Zhang H; Kantarjian H; Jabbour E; Pierce S; Gocho Y; Roberts KG; Yang W; Mullighan CG; Yang J; Konopleva M; Jain N
Am J Hematol; 2021 Mar; 96(3):E71-E74. PubMed ID: 33275800
[No Abstract] [Full Text] [Related]
2. GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Madzio J; Pastorczak A; Sedek L; Braun M; Taha J; Wypyszczak K; Trelinska J; Lejman M; Muszynska-Roslan K; Tomasik B; Derwich K; Koltan A; Kazanowska B; Irga-Jaworska N; Badowska W; Matysiak M; Kowalczyk J; Styczynski J; Fendler W; Szczepanski T; Mlynarski W
Genes Chromosomes Cancer; 2019 Sep; 58(9):619-626. PubMed ID: 30859636
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Jorgensen JL; Cortes J; Faderl S; Garcia-Manero G; Verstovsek S; Koller C; Pierce S; Huh Y; Wierda W; Keating MJ; Kantarjian HM
Blood; 2009 Jun; 113(25):6330-7. PubMed ID: 18703706
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
5. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
[TBL] [Abstract][Full Text] [Related]
6. ABL deletion without associated BCR-ABL in precursor B-cell acute lymphoblastic leukemia.
Lo A; Gu G; Liu M; Dev VG
Leuk Res; 2009 Aug; 33(8):e98-103. PubMed ID: 19282030
[No Abstract] [Full Text] [Related]
7. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Harvey RC; Mullighan CG; Chen IM; Wharton W; Mikhail FM; Carroll AJ; Kang H; Liu W; Dobbin KK; Smith MA; Carroll WL; Devidas M; Bowman WP; Camitta BM; Reaman GH; Hunger SP; Downing JR; Willman CL
Blood; 2010 Jul; 115(26):5312-21. PubMed ID: 20139093
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Messinger YH; Gaynon PS; Sposto R; van der Giessen J; Eckroth E; Malvar J; Bostrom BC;
Blood; 2012 Jul; 120(2):285-90. PubMed ID: 22653976
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Schmäh J; Fedders B; Panzer-Grümayer R; Fischer S; Zimmermann M; Dagdan E; Bens S; Schewe D; Moericke A; Alten J; Bleckmann K; Siebert R; Schrappe M; Stanulla M; Cario G
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28371317
[TBL] [Abstract][Full Text] [Related]
10. Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia.
Zhang H; Liu AP; Devidas M; Lee SH; Cao X; Pei D; Borowitz M; Wood B; Gastier-Foster JM; Dai Y; Raetz E; Larsen E; Winick N; Bowman WP; Karol S; Yang W; Martin PL; Carroll WL; Pui CH; Mullighan CG; Evans WE; Cheng C; Hunger SP; Relling MV; Loh ML; Yang JJ
J Natl Cancer Inst; 2021 Apr; 113(4):408-417. PubMed ID: 32894760
[TBL] [Abstract][Full Text] [Related]
11. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
Horibe K; Yumura-Yagi K; Kudoh T; Nishimura S; Oda M; Yoshida M; Komada Y; Hara J; Tawa A; Usami I; Tanizawa A; Kato K; Kobayashi R; Matsuo K; Hori H;
J Pediatr Hematol Oncol; 2017 Mar; 39(2):81-89. PubMed ID: 28169879
[TBL] [Abstract][Full Text] [Related]
12. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Tutor O; Díaz MA; Ramírez M; Algara P; Madero L; Martínez P
Leuk Res; 2002 Sep; 26(9):817-20. PubMed ID: 12127556
[TBL] [Abstract][Full Text] [Related]
14. Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposure.
Layden BT; Joseph M; Tallman MS; Platanias LC
Acta Haematol; 2007; 118(4):242-3. PubMed ID: 18087146
[TBL] [Abstract][Full Text] [Related]
15. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
Cassaday RD; Stevenson PA; Wood BL; Becker PS; Hendrie PC; Sandmaier BM; Radich JL; Shustov AR
Am J Hematol; 2018 Aug; 93(4):546-552. PubMed ID: 29318644
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Short NJ; Kantarjian HM; Ko H; Khoury JD; Ravandi F; Thomas DA; Garcia-Manero G; Khouri M; Cortes JE; Wierda WG; Verstovsek S; Estrov Z; Ferrajoli A; Thompson PA; Pierce S; O'Brien SM; Jabbour E
Am J Hematol; 2017 Jun; 92(6):E114-E117. PubMed ID: 28295472
[No Abstract] [Full Text] [Related]
17. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
Chen YC; Ho CL; Kao WY; Hwang JM; Sheu LF; Chao TY
Ann Hematol; 2001 Nov; 80(11):647-52. PubMed ID: 11757723
[TBL] [Abstract][Full Text] [Related]
18. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Testi AM; Canichella M; Vitale A; Piciocchi A; Guarini A; Starza ID; Cavalli M; De Propris MS; Messina M; Elia L; Moleti ML; Martino B; Luppi M; D'Aloisio M; Candoni A; Conter V; Fazi P; Vignetti M; Chiaretti S; Foà R
Am J Hematol; 2021 Mar; 96(3):292-301. PubMed ID: 33284999
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute lymphoblastic leukemia in adults.
Barbui T; Bassan R; Chisesi T; Battista R; Cortelazzo S; Rodeghiero F; Capnist G; D'Emilio A; Viero P; Dini E
Hematol Oncol; 1985; 3(1):49-53. PubMed ID: 3857210
[TBL] [Abstract][Full Text] [Related]
20. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.
Chiaretti S; Brugnoletti F; Messina M; Paoloni F; Fedullo AL; Piciocchi A; Elia L; Vitale A; Mauro E; Ferrara F; De Fabritiis P; Luppi M; Ronco F; De Propris MS; Raponi S; Kronnie GT; Vignetti M; Guarini A; Foà R
Leuk Res; 2016 Feb; 41():36-42. PubMed ID: 26754556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]